Expect downward pressure on ORKA stock as the market prices in dilution from this large follow-on. Monitor pricing of the offerings and any concurrent news on clinical pipeline or cash burn. The second undisclosed offering adds uncertainty.
Price Chart
Executive Summary
Oruka Therapeutics filed two preliminary prospectus supplements for a combined equity offering of at least $500 million (plus $75 million overallotment) under its $1 billion shelf registration. The company estimates $496 million cash on hand as of March 31, 2026, and intends to use proceeds for general corporate purposes including R&D and working capital. The substantial dilution from this large follow-on offering is bearish for the stock.
Key Facts
- Offering $500,000,000 of common stock and pre-funded warrants, plus underwriter option for $75,000,000 additional shares
- Second concurrent common stock offering of undisclosed amount (placeholder $[] )
- Cash, cash equivalents, and investments approximately $496 million as of March 31, 2026
- Historical net tangible book value of $471.9 million ($9.69 per share) as of December 31, 2025
- Stock price $69.03 on April 24, 2026; market cap ~$3.4B
Financial Impact
Dilution of at least 15-20% of market cap from $500M+ offering; exact dilution depends on pricing and size of second offering
Risk Factors
- Significant equity dilution diluting existing shareholders
- Potential further offerings if all of $1B shelf is utilized
- No revenue or profitability to offset dilution concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (ORKA) — Batch item 1 | 0001213900-26-048099 |
| Document: 0001213900-26-048099-index-headers.html | 0001213900-26-048100 |
| Document: 0001213900-26-048099-index.html | 0001213900-26-048099 |
| Document: 0001213900-26-048099.txt | 0001213900-26-048099 |
| 424B5 Filing (ORKA) — Batch item 5 | 0001213900-26-048100 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access